Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CCCC C4 Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CCCC
Price (delayed)
$1.38
Market cap
$97.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.47
Enterprise value
$107.62M
C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment
Highlights
CCCC's gross profit has surged by 99% year-on-year and by 12% since the previous quarter
The company's revenue has surged by 99% YoY and by 12% QoQ
C4 Therapeutics's equity has decreased by 24% YoY and by 10% QoQ
Key stats
What are the main financial stats of CCCC
Market
Valuations
Earnings
Shares outstanding
71.01M
Market cap
$97.99M
Enterprise value
$107.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
2.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.71
Revenue
$39.78M
Gross profit
$39.78M
Operating income
-$116.56M
Net income
-$103.28M
EBIT
-$103.15M
EBITDA
-$94.83M
Free cash flow
-$80.5M
Per share
Balance sheet
Liquidity
EPS
-$1.47
EPS diluted
-$1.47
Free cash flow per share
-$1.14
Book value per share
$2.75
Revenue per share
$0.56
TBVPS
$4.51
Total assets
$319.52M
Total liabilities
$124.38M
Debt
$64.37M
Equity
$195.14M
Working capital
$191.72M
Debt to equity
0.33
Current ratio
5.7
Quick ratio
5.55
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
-238.4%
Gross margin
100%
Net margin
-259.6%
Operating margin
-293%
Return on assets
-29%
Return on equity
-45.9%
Return on invested capital
-32.9%
Return on capital employed
-37%
Return on sales
-259.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CCCC stock price
How has the C4 Therapeutics stock price performed over time
Intraday
0%
1 week
-6.12%
1 month
25.45%
1 year
-76.88%
YTD
-61.67%
QTD
-13.75%
Financial performance
How have C4 Therapeutics's revenue and profit performed over time
Revenue
$39.78M
Gross profit
$39.78M
Operating income
-$116.56M
Net income
-$103.28M
Gross margin
100%
Net margin
-259.6%
CCCC's gross profit has surged by 99% year-on-year and by 12% since the previous quarter
The company's revenue has surged by 99% YoY and by 12% QoQ
The company's net margin has surged by 59% YoY and by 12% QoQ
The operating margin has soared by 57% YoY and by 13% from the previous quarter
Price vs fundamentals
How does CCCC's price correlate with its fundamentals
Growth
What is C4 Therapeutics's growth rate over time
Valuation
What is C4 Therapeutics stock price valuation
P/E
N/A
P/B
0.5
P/S
2.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.71
The EPS has increased by 38% year-on-year and by 3.3% since the previous quarter
The price to book (P/B) is 78% lower than the 5-year quarterly average of 2.3 and 58% lower than the last 4 quarters average of 1.2
C4 Therapeutics's equity has decreased by 24% YoY and by 10% QoQ
The company's revenue has surged by 99% YoY and by 12% QoQ
CCCC's price to sales (P/S) is 87% less than its 5-year quarterly average of 19.3 and 70% less than its last 4 quarters average of 8.1
Efficiency
How efficient is C4 Therapeutics business performance
The return on sales has surged by 58% year-on-year and by 12% since the previous quarter
C4 Therapeutics's return on invested capital has increased by 16% YoY
The company's return on assets rose by 15% YoY but it fell by 3.6% QoQ
C4 Therapeutics's ROE has increased by 13% YoY but it has decreased by 5% from the previous quarter
Dividends
What is CCCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CCCC.
Financial health
How did C4 Therapeutics financials performed over time
C4 Therapeutics's total assets is 157% more than its total liabilities
C4 Therapeutics's total assets has decreased by 20% YoY and by 9% from the previous quarter
The current ratio is up by 12% YoY
The company's debt is 67% lower than its equity
C4 Therapeutics's equity has decreased by 24% YoY and by 10% QoQ
CCCC's debt to equity is up by 22% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.